|title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA Approval & Treatment Guid
|description=Comprehensive guide to Tumor Treating Fields (TTFields) therapy using Optune Lua for malignant pleural mesothelioma. Covers STELLA
...
64 KB (8,231 words) - 09:57, 6 April 2026
...), immunotherapy (nivolumab-ipilimumab, pembrolizumab), radiation therapy, TTFields, CAR-T cell therapy, multimodal approaches, and palliative care.
...decortication, extrapleural pneumonectomy, radiation therapy mesothelioma, TTFields mesothelioma, CAR-T mesothelioma, palliative care mesothelioma, mesotheliom
...
55 KB (6,918 words) - 12:35, 6 April 2026
* '''TTFields is the only cost-effective mesothelioma treatment''' — at $89,808 per QALY
...per month based on manufacturer pricing. A cost-effectiveness study found TTFields added an average of $59,663 in lifetime costs compared to standard therapy,
...
39 KB (4,954 words) - 23:00, 8 March 2026
=== Tumor Treating Fields (TTFields) ===
...the 2025 ASCO guideline states there is insufficient evidence to recommend TTFields, citing very low quality evidence.<ref name="asco2025" />
...
48 KB (5,851 words) - 22:11, 8 March 2026
=== Tumor Treating Fields (TTFields) ===
...
25 KB (3,138 words) - 20:56, 20 February 2026
| style="padding:10px;" | TTFields (Optune Lua)
...
14 KB (1,830 words) - 09:56, 6 April 2026
* '''Tumor Treating Fields (TTFields):''' Multi-hospital review studying TTFields for mesothelioma; emerging data from combination with standard chemotherapy
...vances (2025): CAR-T, CRISPR, viral gene therapy, BAP1-targeted therapies, TTFields, combination immunotherapy + gene therapy. Mesothelioma Attorney, https://m
...
43 KB (5,354 words) - 03:51, 9 March 2026
...tments with rigorous monitoring. Both CheckMate 743 and the STELLAR trial (TTFields) demonstrated meaningful survival improvements over standard care.<ref name
...larly immunotherapy (nivolumab plus ipilimumab) and tumor treating fields (TTFields) — have meaningfully improved survival expectations since 2020. Additionall
...
41 KB (5,121 words) - 20:56, 8 March 2026
...vs. 6%), pembrolizumab/pemetrexed/platinum (September 17, 2024; HR 0.79); TTFields device (HDE only, 2019)<ref name="dandell-meso" /><ref name="keynote-483" /
...l has been registered, and NCCN/ASCO guidelines do not prominently feature TTFields due to the absence of randomized data.<ref name="mesonet-treatment" />
...
62 KB (7,831 words) - 01:11, 6 April 2026
* [[TTFields Optune Lua]]
...
27 KB (3,530 words) - 04:00, 9 March 2026
...ural Mesothelioma]] — Immunotherapy, MARS 2 trial, CAR-T cell therapy, and TTFields
...
23 KB (2,626 words) - 01:08, 6 April 2026
=== Tumor Treating Fields (TTFields/Optune) ===
'''Definition:''' Tumor Treating Fields (TTFields), delivered through the Optune Lua device, is a novel treatment that uses l
...
216 KB (26,444 words) - 23:30, 23 January 2026
...padding:10px; border-bottom:1px solid #dee2e6;" | '''[[TTFields_Optune_Lua|TTFields (Optune Lua)]]'''
* [[TTFields_Optune_Lua|TTFields / Optune Lua for Mesothelioma]]
...
67 KB (8,763 words) - 09:18, 6 April 2026
'''Tumor Treating Fields (TTFields):''' The Optune Lua device, approved via the FDA's Humanitarian Device Exem
* Tumor Treating Fields (TTFields/Optune Lua) combined with chemotherapy achieved median OS of 18.2 months in
...
59 KB (7,425 words) - 01:11, 6 April 2026
| style="padding:10px;" | TTFields + chemotherapy improves survival
...
38 KB (4,755 words) - 03:42, 9 March 2026
...ilimumab immunotherapy]], [[CAR-T Cell Therapy|CAR-T cell therapy]], and [[TTFields Optune Lua|tumor treating fields]] — will require updated protocols for man
...
71 KB (9,109 words) - 09:57, 6 April 2026
* [[TTFields_Optune_Lua|TTFields / Optune Lua for Mesothelioma]]
...
66 KB (8,673 words) - 02:53, 4 March 2026
* '''Tumor treating fields (TTFields):''' Non-invasive electrical field therapy<ref>[https://mesothelioma.net/me
...
220 KB (28,527 words) - 01:11, 6 April 2026
